This diabetes technology offers a continuous stream of data to show a more complete picture of your blood sugars over time. This is different from a fingerstick meter that only represents that moment.

At long last, Eversense, the implantable continuous glucose monitoring system from Senseonics, has received FDA clearance to be marketed in the United States. “The FDA is committed to advancing novel ...

GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, ...

The US Food and Drug Administration (FDA) has approved the first-ever implantable continuous glucose monitoring system, the Eversense CGM (Senseonics), for people aged 18 years and older with diabetes ...

DETROIT, MICHIGAN - March 19, 2025 (NEWMEDIAWIRE) - Paul Goode, President & CEO, GlucoTrack (NASDAQ: GCTK), was recently a guest on Benzinga's All-Access. GlucoTrack is a medical technology company ...

By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a ...

GluSense, an Israeli medical device company, announced an undisclosed investment from the JDRF T1D Fund, a recently launched VC philanthropy fund dedicated to funding early stage programs for Type 1 ...

Glucotrack, a diabetes-focused medtech company, today announced the beginning of patient enrollment for its short-term human clinical trial examining the company’s continuous blood glucose monitor ...

Detailed price information for Senseonics Holdings Inc (SENS-Q) from The Globe and Mail including charting and trades.

Don’t miss this exclusive opportunity to explore a groundbreaking innovation that could reshape how diabetes is managed. Join us for an inside look at Glucotrack, a cutting-edge medical technology ...